Found: 48
Select item for more details and to access through your institution.
Bioequivalence of recombinant factor VIII products: a position paper from the Italian Association of Hemophilia Centers.
- Published in:
- Blood Transfusion (17232007), 2023, v. 21, n. 5, p. 441, doi. 10.2450/2023.0235-22
- By:
- Publication type:
- Article
Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management.
- Published in:
- Blood Transfusion (17232007), 2018, v. 16, n. 6, p. 535, doi. 10.2450/2017.0150-17
- By:
- Publication type:
- Article
The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A.
- Published in:
- Blood Transfusion (17232007), 2017, v. 15, n. 3, p. 281, doi. 10.2450/2017.0285-16
- By:
- Publication type:
- Article
Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.
- Published in:
- Blood Transfusion (17232007), 2017, v. 15, n. 1, p. 77, doi. 10.2450/2015.0127-15
- By:
- Publication type:
- Article
Tailoring care to haemophilia patients' needs: which specialty and when?
- Published in:
- Blood Transfusion (17232007), 2015, v. 13, n. 4, p. 644, doi. 10.2450/2015.0302-14
- By:
- Publication type:
- Article
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.
- Published in:
- Blood Transfusion (17232007), 2015, v. 13, n. 3, p. 498, doi. 10.2450/2015.0141-15
- By:
- Publication type:
- Article
Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.
- Published in:
- Blood Transfusion (17232007), 2014, v. 12, n. 4, p. 575, doi. 10.2450/2014.0223-14
- By:
- Publication type:
- Article
Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders.
- Published in:
- Blood Transfusion (17232007), 2014, v. 12, p. s582, doi. 10.2450/2014.0087-14s
- By:
- Publication type:
- Article
Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future.
- Published in:
- Blood Transfusion (17232007), 2014, v. 12, n. 3, p. 314, doi. 10.2450/2014.0298-13
- By:
- Publication type:
- Article
Current and evolving features in the clinical management of haemophilia.
- Published in:
- Blood Transfusion (17232007), 2014, v. 12, p. s554, doi. 10.2450/2014.0043-14s
- By:
- Publication type:
- Article
Current status of Italian Registries on inherited bleeding disorders.
- Published in:
- Blood Transfusion (17232007), 2014, v. 12, p. s576, doi. 10.2450/2014.0017-14s
- By:
- Publication type:
- Article
Clinical use of factor VIII and factor IX concentrates.
- Published in:
- Blood Transfusion (17232007), 2013, v. 11, p. s55, doi. 10.2450/2013.010s
- By:
- Publication type:
- Article
Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course -- the Kogeniale project.
- Published in:
- Blood Transfusion (17232007), 2013, v. 11, n. 2, p. 272, doi. 10.2450/2012.0158-12
- By:
- Publication type:
- Article
The Relationship between Inflammatory Cytokines and Coagulopathy in Patients with COVID-19.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 9, p. 2020, doi. 10.3390/jcm10092020
- By:
- Publication type:
- Article
The History of Clotting Factor Concentrates Pharmacokinetics.
- Published in:
- Journal of Clinical Medicine, 2017, v. 6, n. 3, p. 35, doi. 10.3390/jcm6030035
- By:
- Publication type:
- Article
Managing Relevant Clinical Conditions of Hemophilia A/B Patients.
- Published in:
- Hematology Reports, 2023, v. 15, n. 2, p. 384, doi. 10.3390/hematolrep15020039
- By:
- Publication type:
- Article
Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A.
- Published in:
- Patient Preference & Adherence, 2019, v. 13, p. 233, doi. 10.2147/PPA.S175254
- By:
- Publication type:
- Article
No Hepatitis After Treatment with a Modified Factor IX Concentrate in Previously Untreated Hemophiliacs.
- Published in:
- Annals of Internal Medicine, 1985, v. 103, n. 2, p. 226, doi. 10.7326/0003-4819-103-2-226
- By:
- Publication type:
- Article
Recent Advances in the Treatment of Hemophilia: A Review.
- Published in:
- Biologics: Targets & Therapy, 2021, v. 15, p. 221, doi. 10.2147/BTT.S252580
- By:
- Publication type:
- Article
Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 6, p. 1182, doi. 10.1111/bjh.16490
- By:
- Publication type:
- Article
Prophylaxis with Recombinant Activated Factor VII in Hemophilia Patients with Inhibitors.
- Published in:
- Journal of Coagulation Disorders, 2010, v. 2, n. 2, p. 1
- By:
- Publication type:
- Article
Prophylaxis with Recombinant Activated Factor VII in Hemophilia Patients with Inhibitors.
- Published in:
- Journal of Coagulation Disorders, 2010, v. 2, n. 1, p. 1
- By:
- Publication type:
- Article
Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 17, p. 4986, doi. 10.3390/jcm13174986
- By:
- Publication type:
- Article
Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 3, p. 733, doi. 10.3390/jcm11030733
- By:
- Publication type:
- Article
Low risk of transmission of the human immunodeficiency virus by a solvent-detergent-treated commercial factor VIII concentrate.
- Published in:
- Journal of Medical Virology, 1992, v. 36, n. 2, p. 71, doi. 10.1002/jmv.1890360202
- By:
- Publication type:
- Article
INDIVIDUALIZATION OF FACTOR VIII DOSAGE.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 1984, v. 9, n. 2, p. 95, doi. 10.1111/j.1365-2710.1984.tb01065.x
- By:
- Publication type:
- Article
Practical aspects of extended half-life products for the treatment of haemophilia.
- Published in:
- Therapeutic Advances in Hematology, 2018, v. 9, n. 9, p. 295, doi. 10.1177/2040620718796429
- By:
- Publication type:
- Article
Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.
- Published in:
- Therapeutic Advances in Hematology, 2018, v. 9, n. 6, p. 149, doi. 10.1177/2040620718774258
- By:
- Publication type:
- Article
Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 2, p. 111, doi. 10.1111/ejh.13193
- By:
- Publication type:
- Article
Outcome measures for adult and pediatric hemophilia patients with inhibitors.
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 2, p. 103, doi. 10.1111/ejh.12881
- By:
- Publication type:
- Article
Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.
- Published in:
- European Journal of Haematology, 2016, v. 96, n. 2, p. 111, doi. 10.1111/ejh.12631
- By:
- Publication type:
- Article
Switching treatments in haemophilia: is there a risk of inhibitor development?
- Published in:
- European Journal of Haematology, 2015, v. 94, n. 4, p. 284, doi. 10.1111/ejh.12433
- By:
- Publication type:
- Article
Innovative approach for improved r FVIII concentrate.
- Published in:
- European Journal of Haematology, 2014, v. 93, n. 5, p. 361, doi. 10.1111/ejh.12359
- By:
- Publication type:
- Article
Angiogenesis is increased in advanced haemophilic joint disease and characterised by normal pericyte coverage.
- Published in:
- European Journal of Haematology, 2014, v. 92, n. 3, p. 256, doi. 10.1111/ejh.12227
- By:
- Publication type:
- Article
Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.
- Published in:
- European Journal of Haematology, 2012, v. 88, n. 5, p. 371, doi. 10.1111/j.1600-0609.2012.01754.x
- By:
- Publication type:
- Article
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Anti-TNF-α therapy prevents the recurrence of joint bleeding in haemophilia and arthritis.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.
- Published in:
- British Journal of Haematology, 2004, v. 126, n. 3, p. 398, doi. 10.1111/j.1365-2141.2004.05058.x
- By:
- Publication type:
- Article
A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation.
- Published in:
- British Journal of Haematology, 2003, v. 120, n. 5, p. 808, doi. 10.1046/j.1365-2141.2003.04173.x
- By:
- Publication type:
- Article
Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.
- Published in:
- Italian Journal of Pediatrics, 2015, v. 41, n. 1, p. 1, doi. 10.1186/s13052-015-0116-8
- By:
- Publication type:
- Article
Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors.
- Published in:
- Haemophilia, 2023, v. 29, n. 2, p. 479, doi. 10.1111/hae.14722
- By:
- Publication type:
- Article
Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors.
- Published in:
- Haemophilia, 2021, v. 27, n. 3, p. 340, doi. 10.1111/hae.14167
- By:
- Publication type:
- Article
Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long‐term experience at a single Haemophilia centre.
- Published in:
- Haemophilia, 2021, v. 27, n. 1, p. e93, doi. 10.1111/hae.14169
- By:
- Publication type:
- Article
Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients.
- Published in:
- Haemophilia, 2019, v. 25, n. 6, p. e364, doi. 10.1111/hae.13828
- By:
- Publication type:
- Article
Efficacy and safety of a VWF/ FVIII concentrate (wilate<sup>®</sup>) in inherited von Willebrand disease patients undergoing surgical procedures.
- Published in:
- Haemophilia, 2017, v. 23, n. 2, p. 264, doi. 10.1111/hae.13106
- By:
- Publication type:
- Article
Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
- Published in:
- Haemophilia, 2014, v. 20, n. 4, p. e243, doi. 10.1111/hae.12456
- By:
- Publication type:
- Article
Personalized Prophylaxis with myPKFiT CE : A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients.
- Published in:
- Medicina (1010660X), 2024, v. 60, n. 1, p. 34, doi. 10.3390/medicina60010034
- By:
- Publication type:
- Article
Identification of seven novel mutations of F8C by DHPLC.
- Published in:
- Human Mutation, 2002, v. 20, n. 3, p. 231, doi. 10.1002/humu.9052
- By:
- Publication type:
- Article